Xiong, Yuquan
Taleb, Meriem http://orcid.org/0009-0002-7820-6829
Misawa, Kyohei
Hou, Zhaohua
Banerjee, Srijita
Amador-Molina, Alfredo
Jones, David R. http://orcid.org/0000-0002-3318-0146
Chintala, Navin K. http://orcid.org/0000-0003-4229-0977
Adusumilli, Prasad S. http://orcid.org/0000-0002-1699-2046
Funding for this research was provided by:
Foundation for the National Institutes of Health (P30 CA008748, R01 CA236615-01, R01 CA235667, U01 CA214195)
U.S. Department of Defense (CA170630, CA180889, CA200437)
Article History
Received: 30 June 2022
Accepted: 8 May 2023
First Online: 19 June 2023
Competing interests
: Y.X. and P.S.A. have a pending patent application on the KITv mutation as a co-stimulatory domain to use in T cells. P.S.A. declares research funding from ATARA Biotherapeutics and Novocure; is a scientific advisory board member and consultant for Adjuvant Genomics, ATARA Biotherapeutics, Abound Bio, Bio4t2, Carisma Therapeutics, Imugene, ImmPACT Bio, Johnson & Johnson, Link Immunotherapeutics, Orion Pharma, Outpace Bio, Pluri-biotech, Putnam Associates and Verismo Therapeutics; has patents, royalties and intellectual property on MSLN-targeted CAR and other T cell therapies licensed to ATARA Biotherapeutics; has issued a patent method for the detection of cancer cells using virus; and has pending patent applications on PD-1 dominant-negative receptors, a wireless pulse-oximetry device and an ex vivo malignant pleural effusion culture system. All other authors declare no competing interests. Memorial Sloan Kettering Cancer Center has licensed intellectual property related to MSLN-targeted CARs and T cell therapies to ATARA Biotherapeutics and has associated financial interests.